Milk, Cheese, Dairy Products May Cut Diabetes Risk

Harvard scientists have identified a natural substance in dairy fat that may substantially reduce the risk of type 2 diabetes.

According to the researchers, the compound, trans-palmitoleic (TP) acid, is a fatty acid found in milk, cheese, yogurt, and butter. It is not produced by the body and so only comes from the diet.  Diabetes is an increasingly common condition that can result in disability for older individuals according to the American Association for Long-Term Care Insurance.

A report in the Annals of Internal Medicine explains that TP acid may underlie epidemiological evidence in recent years that diets rich in dairy foods are linked to lower risk of type 2 diabetes and related metabolic abnormalities. Health experts generally advise reducing full-fat dairy products, but TP acid is found in dairy fat.

The researchers examined nearly 4,000 participants and followed them for 20 years in an observational study to evaluate risk factors for cardiovascular diseases in older adults. Metabolic risk factors such as blood glucose and insulin levels, and also levels of circulating blood fatty acids, including trans-palmitoleic acid, were measured using stored blood samples in 1992, and participants were followed for development of type 2 diabetes.

At baseline, higher circulating levels of TP acid were associated with healthier levels of blood cholesterol, inflammatory markers, insulin levels, and insulin sensitivity, after adjustment for other risk factors.

During follow-up exams, individuals with higher circulating levels of trans-palmitoleic acid had a much lower risk of developing diabetes, with about a 60% lower risk among participants in the highest quintile (fifth) of TP acid levels, compared to individuals in the lowest quintile.

Support for the study was provided by the National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health and the National Institutes of Health Office of Dietary Supplements and National Institute of Neurological Disorders and Stroke.

Discovery Could Treat Obesity-Related Diabetes And Heart Disease

Researchers have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes and heart disease.

The medical scientists found that action by the enzyme histone deacetylase 9 (HDAC9) could be targets for potential treatment options in obesity-related diseases.

Researchers were really interested in the tie between increased HDAC9 levels in fat tissue of mice and the caloric overload.  Fat tissues from these obese mice showed dysfunction, with increased expression of pro-inflammatory agents and decreased expression of hormones responsible for maintaining whole body lipid and glucose stability.

HDAC9 level in fat cells is the underlying molecular culprit for dysfunctional fat tissue during obesity.

The researchers are currently examining HDAC9 knockout mice subjected to chronic high-fat feeding and think that HDAC9 gene removal will protect mice from obesity-linked adipose tissue dysfunction and associated metabolic disorders.

The team is pursuing studies to understand how diet regulates HDAC9 levels in fat tissue and how HDAC9 up-regulation can be prevented during diet-induced obesity through pharmacological means.  Their findings may help lead researchers to targeted therapies that may prevent the development of obesity-related disorders in humans reports the American Association for Long-Term Care Insurance which tracks scientific research impacting the long-term health of Americans.